tbuckley/cabot-search huggingface dataset:
The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation – a Phase II Study
Authors: Biju George, Auro Viswabandya, Ansu Abu Alex, Kavitha M Lakshmi, Aby Abraham, Abhijeet Ganapule, Fouzia N, Alok Srivastava, Vikram Mathews
Journal: Blood (2014)
The Tumor Suppressor Gene SLC5A8 Is Selectively Silenced in MLL Partial Tandem Duplication-Positive Acute Myeloid Leukemia with Normal Cytogenetics.
Authors: Susan P. Whitman, Jing Wen, Gina Muto, Bjoern Hackanson, Li Yu, Chunhui Liu, Joseph L. Sanfilippo, Guido Marcucci, Laura J. Rush, Christoph Plass, Michael A. Caligiuri
Journal: Blood (2006)
Breast Cancer Resistance Protein (BCRP) Expression Affects Event-Free Survival in Adult Acute Lymphoblastic Leukemia Patients Uniformly Treated According to the GIMEMA LAL 2000 Protocol.
Authors: Chiara Gregorj, Maria T. Petrucci, Fabiana De Cave, Maria C. Scerpa, Maria R. Ricciardi, Jacopo Gervasoni, Maria L. Iannitto, Marco Vignetti, Paola Fazi, Antonella Vitale, Giovanna Meloni, Vincenzo Liso, Francesco Di Raimondo, Felicetto Ferrara, Francesco Fabbiano, Andrea Camera, Giuseppe Fioritoni, Eustachio Miraglia, Luciana Annino, Nicola Cascavilla, Filippo Marmont, Patrizio Mazza, Omar Perbellini, Nicola Cantone, Mario Luppi, Francesco Nobile, Simona Sica, Flavia Salvi, Robin Foa’, Agostino Tafuri
Journal: Blood (2005)
Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.
Authors: Maike Nickelsen, Carmen Canals, Charalampia Kyriakou, Norbert Schmitz, Agnes Buzyn, Monika Engelhardt, Bertram Glass, Eulogio Conde, Armando Lopez-Guillermo, Gerard Socie, Anna Sureda
Journal: Blood (2008)
AB0094 A Dual Pathomechnism of Local TNF Produceing IGA B Cells in RA Synovial Tissue
Authors: Z. Konthur, U. Nonhoff, M.M. Wiemkes, J. Detert, T. Braun, J.M. Hollidt, G.R. Burmester, K. Skriner
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> So far no mechanism for non response to biologicals targeting TNFα has been described despite one third of rheumatoid arthritis patients treated are non-responders. <h3>Objectives</h3> We investigated the differences in seroreactivity of patients responding and not responding to TNF therapies prior and after therapy and identified diagnostically applicable IgA autoantigenicity set to identify non response. <h3>Methods</h3> Screening with patient sera were conducted with 5 different roteins candidates which were identified by protein maroarray screening (Anal Biochem. 1999 May 15;270(1):103–11.9) expressed recombinantly in <i>E. coli</i>, purified and further stratified with a large well defined patient cohort by ELISA. Baseline sera form PREDICT trial treated with Enbrel) and patients treated with Humira in the HIT HARD (Ann Rheum Dis. 2013 Jun;72(6):844–509 trial and 66 baseline sera from Charite in addition treated with (Cimzia, Infiximab) were ivestigated by Pre. mark TNF ELISA from DRDx GmbH. <h3>Results</h3> Pretreatment sera from patients with diagnosis of RA based on the ACR classification criteria who were initiated on therapy with TNFalpha inhibitors were analyzed with five markers from the biomarker set of highest priority (RAB11B, PPP2R1A, KPNB1,Cog 4, FTFT1) using an ELISAs assay. In total, analyses of 203 patients were carried out, of which 162 were clearly defined as Responder and 41 were clearly defined as non-Responder after 6 month treatment. 81% of Non-responder could be clearly identified with the pre.markTNF Test. The assay has currently a specificity 94%. Moreover, 80 baseline serum samples from the PREDICT study with Enbrel and 57 baseline sera from an early intervention trial Hit Hard (Ann Rheum Dis. 2013 Jun;72(6):844–509) with Humira were analysed. In early subset, all 3 non-responder were identified and the specificity of the assay was 98%. In the PREDICT study Enbrel non responders were identified with 68.8% sensitivity and a specificity of 92.5%. Moreover 60 patients treated with TNFalpha inhibitors TNF from Stockholm and Vienna have been tested with &gt;90% specificity to predict non response. The amount of IgA produceing B cell in the synovia differs significantly between the patients which is not seen with IgG produceing B cells. Moreover the potent IgA autoantibodies induce high amount of TNF alpha in marophage assay were IgG do not. A dual pathomechnism of local TNF produceing IgA B cells in RA synovial tissue and TNF produceing macrophages is proposed. <h3>Conclusions</h3> These data suggest that non-response to anti-TNFα biologicals might be predicted based on frequency and magnitude of autoantibodies to specific IgA autoantigens. SFB can stimulate multiple intestinal homeostatic IgA and TNF induceing B cells might be important for disease persistence in TNFα non responders. <h3>Disclosure of Interest</h3> None declared
SAT0172 Comparison of Efficacy and Safety of Biologic Agents between Elderly-Onset and Younger-Onset Rheumatoid Arthritis
Authors: K. Fujita, Y. Yamamura, Y. Nomura, N. Shibutou, A. Ueno, K. Maruyama, T. Ombe, M. Hiramatsu, M. Yamamura
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There are pathogenetic and clinical differences between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA). <h3>Objectives</h3> To compare the efficacy and safety of biologic agents between patients with EORA and those with YORA. <h3>Methods</h3> A total of 61 patients with RA, who started biologic agents after the age of 65 years, have been enrolled from April 2011 to August 2015, and divided into two groups according to the age at disease onset; i.e. EORA ≥65 years and YORA &lt;65 years. Biologic agents were grouped into 3 classes; the TNF-alpha inhibitors (TNFi) including infliximab, etanercept, adalimumab, golimumab and certolizumab pegol, the CTLA4-Ig abatacept (ABT) and the IL-6 inhibitor tocilizumab (TCZ). Forty-four patients with EORA have received 64 biologic agents (36 women and 8 men; average ± SD age, 76.1 ± 5.7 years; disease duration, 2.0 ± 3.4 years; rheumatoid factor (RF)/anti-cyclic citrullinated peptide antibody (ACPA) positive, 63.6%/65.9%), and 17 patients have received 29 biologic agents (13 women and 4 men; average age, 71.2 ± 4.9 years; disease duration, 17.8 ± 13.9 years; RF/ACPA positive, 76.5%/70.6%). The disease activity was measured according as simplified disease activity index (SDAI), and the efficacy was determined by the induction rate of remission (SDAI ≤3.3) and low-disease activity (3.3 &lt; SDAI ≤11). <h3>Results</h3> The EORA patient group did respond better to biologic agents than the YORA patient group; the SDAI was significantly lower in the former than in the latter. At present, there were no significant differences in responses to TNFi, ABT and TCZ between the 2 patient gourps (Table 1). Both patient groups developed adverse events during biologic therapy, and severe adverse events including cholecystitis, pulmonary cryptococcosis, diverticulitis, malignant lymphoma, Pneumocystis pneumonia, organizing pneumonia and so on. <h3>Conclusions</h3> The results indicate that biologic agents are similarly effective for both EORA and YORA patients, irrelevant to different classes, but patients with EORA appears to be more responsive to biologics than YORA patients, presumably due to their shorter disease duration. <h3>Disclosure of Interest</h3> None declared
Evaluation of the Gene Xpert DX System for Molecular Monitoring in CML
Authors: Ghayathri Jeyakumar, Hagop M. Kantarjian, Alfonso Quintas-Cardama, Elias J. Jabbour, Farhad Ravandi, Deborah A. Thomas, Srdan Verstovsek, Jairo Matthews, Susan M. O'Brien, Jorge E. Cortes
Journal: Blood (2012)
AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells.
Authors: Mirna Golemovic, Miloslav Beran, Francis Giles, Taghi Manshouri, Deborah Thomas, Jorge Cortes, Paul Manley, Leila Alland, Patricia Rae, Margaret Dugan, Zeev Estrov, Ralph B. Arlinghaus, Hagop Kantarjian, Srdan Verstovsek
Journal: Blood (2004)
Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis?
Authors: Melanie Tran, Li Wang
Journal: Hepatology (2016)

1Department of Physiology and Neurobiology and the Institute for Systems GenomicsUniversity of ConnecticutStorrsCT 2Veterans Affairs Connecticut Healthcare SystemWest HavenCT 3Department of Internal MedicineSection of Digestive Diseases, Yale UniversityNew HavenCT 4School of Pharmaceutical SciencesWenzhou Medical UniversityWenzhouChina
Growth Inhibition and Induction of Apoptosis in K562 Human Chronic Leukemic Cells by abnobaVISCUM® flaxini, Mistletoe Extracts From Ash Tree: Involvement of Activation of Caspases, Mcl-1 Down-Regulation, and ER Stress
Authors: Young-Rok Do, Yu-Kyung Park, Byeong-Churl Jang, Jin Young Kim, Ki Young Kwon
Journal: Blood (2011)
Novel Therapeutic Approach to Overcome Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma By Targeting TOPK/PBK
Authors: Takayuki Tabayashi, Yasuyuki Takahashi, Yuta Kimura, Tatsuki Tomikawa, Tomoe Nemoto-Anan, Reiko Watanabe, Michihide Tokuhira, Masahiro Kizaki
Journal: Blood (2015)
SAT0112 The Effect of Cardiac Rehabilitation Program on Disease Activity, Functional Outcome and Cardiovascular Risk in Patients with Rheumatoid Arthritis: Table 1
Authors: H. Peynirci Cersit, I. Yagci, S. Cersit, N. Inanc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by symmetric peripheral synovial joint involvement. The most common mortality cause in rheumatoid arthritis (RA) is cardiovascular diseases. Recent guidelines recommend assessment of cardiovascular risk, however the management of cardiovascular risk is not clear. <h3>Objectives</h3> The aims of the study were to find effect of cardiac rehabilitation on disease activity, functional status, fitness and cardiovascular risk score in patients with moderate disease activity. <h3>Methods</h3> Forty seven patients with RA who had filled ACR/EULAR 2010 classification criteria were enrolled to the study. The patients were randomized to cardiac rehabilitation (25 patients) and home based exercise program (22 patients) groups. The intervention in cardiac rehabilitation group included warming, bicycle ergometer, upper and lower extremity stregthening, cooling and stretching exercises. The patients had received cardiac rehabilitation three times a week for 10 weeks. Individualized home exercise program was given to cardiac rehabilitation group after 10th week. The patients in home exercise program were encouraged to do aerobic and strengthening exercises. The patients were evaluated at baseline, 10th and 24th week with exercise tolerance test, 6 minute walking test, DAS28 score, analysis of mSCORE risk profile, HAQ (Stanford Health Assessment Questionnaire), SF36 (Short Form-36) and Beck Depression Scale. <h3>Results</h3> There were significant improvement in the VO2 max, MET level, DAS28, HAQ, SF36- pain, Beck Depression Scale parameters in cardiac rehabilitation group when compared to home exercise group. There was no effect on mSCORE risk profile. <h3>Conclusions</h3> Cardiac rehabilitation improved physical fitness, functional outcomes and decreased disease activity but did not affect mSCORE risk profile. mSCORE risk analysis was seemed to be useful to evaluate cardiovascular risk for 10 years but not for appropriate tool for follow up of cardiac risk. <h3>Disclosure of Interest</h3> None declared
Microbiological swabs have no role in the management of acute pilonidal abscesses
Authors: T. Craven, P.J. Webster, D.A. Burke
Journal: International Journal of Surgery (2016)

criteria.Six studies adopted the use of teamwork training intervention; three studies assessed outcomes based on the familiarity of teams, and two studies correlated teamwork quality with patient outcome.Overall, seven papers demonstrated a positive effect of teamwork on patient outcomes, of which five were significant.Two papers found mixed improvements and deteriorations, two papers found no correlation.There exists considerable heterogeneity in methodology, study characteristics and design.Conclusions: The positive effect of teamwork on surgical patient outcome is overall supported.Insignificant and opposing results are likely due to inadequate methodology and study design.Common reasons identified are cohort size, lack of a validated training programme, length of training and follow-up time, and non-randomization.
Influence of Race and Nutritional Status on the Long Term Event Free Survival in Childhood Acute Lymphoblastic Leukemia (ALL): A 14-year Follow-up with a Reduced BFM-Based Treatment Protocol (GBTLI ALL-93)
Authors: Silvia Regina Brandalise, Maria Pombo-de-Oliveira, Vitoria Régia Pereira Pinheiro, Maria Jose Mastellaro, Waldir Veiga Pereira, Marcos Borato Viana, Luiz Fernando Lopes, Luiz Gonzaga Tone, Maria Lucia Lee, Paula Bruniera, Fernando Almeida Werneck, Sonia Rossi Vianna, Nubia Mendonça, Sandra Regina Loggetto
Journal: Blood (2008)
Chromosomal Aberration Network In Myeloproliferative Neoplasms
Authors: Thorsten Klampfl, Ashot Harutyunyan, Tiina Berg, Bettina Gisslinger, Francesco Passamonti, Elisa Rumi, Daniela Pietra, Damla Olcaydu, Roland Jäger, Mario Cazzola, Heinz Gisslinger, Robert Kralovics
Journal: Blood (2010)
Risk Factors for 30-Day Hospital Readmission Following Myeloablative Allogeneic Stem Cell Transplantation.
Authors: Nelli Bejanyan, Aleksandr Lazaryan, Lisa Rybicki, Shawnda Tench, Steven Andresen, Ronald Sobecks, Robert Dean, Brad Pohlman, Matt Kalaycio, Brian J. Bolwell, Edward A. Copelan
Journal: Blood (2010)
An Open-Label, Phase Ib Study of Duvelisib (IPI-145) in Combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with Lymphoma or Chronic Lymphocytic Leukemia
Authors: Ian Flinn, Manish R. Patel, Michael B Maris, Jeffrey Matous, Mohamad Cherry, Jesus G. Berdeja
Journal: Blood (2014)
AB0502 Prevalence and Clinical Characteristics of Secondary Sjögren's Syndrome and Sicca Symptoms in Patients with Rheumatoid Arthritis in Daily Clinical Practice
Authors: R. Moerman, S. Arends, F. Kroese, F. Spijkervet, E. Brouwer, A. Vissink, H. Bootsma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) can develop sicca symptoms which may be related to secondary Sjögren9s syndrome (sSS). <h3>Objectives</h3> To assess the prevalence and clinical characteristics of sSS in RA patients. <h3>Methods</h3> In this cross-sectional study, 96 consecutive established RA patients referred to our outpatient clinic were submitted to a complete diagnostic work-up for the presence of sSS according to the American-European Consensus Group criteria.[1] Patients underwent clinical examination including DAS-28 score, Schirmer9s test and sialometry of submandibular/sublingual (SM/SL) glands and parotid (PAR) glands. In addition, patients were asked to complete the Health Assessment Questionnaire (HAQ), RAND-36 and Multidimensional Fatigue Inventory (MFI). Clinical characteristics were compared between RA patients fulfilling the criteria for sSS, RA patients with at least one sicca symptom of the eyes or mouth but no sSS and RA patients without sicca symptoms. <h3>Results</h3> Of the 96 included RA patients, 75 (78%) were female, mean age was 54±10 years and median disease duration of RA was 10 years (IQR 5–17). In total, 38 patients (39.6%) reported to have at least one sicca symptom of the eyes or mouth. Six patients (6.3%) were diagnosed with sSS. RA patients with sSS had higher disease activity, lower tears production and lower salivary flow rates compared to patients with and without sicca symptoms. Patients with sicca symptoms used more often xerogenic drugs, had higher disease activity and lower salivary flow rates than patients without sicca symptoms. No differences were found in the proportion of patients that were anti-SSA/SSB antibody positive between the groups. Furthermore, both patients with sSS and patients with sicca symptoms experienced worse physical functioning, lower health-related quality of life and more fatigue than RA patients without sicca symptoms (Table 1). <h3>Conclusions</h3> The prevalence of sicca symptoms and sSS was 39.6% and 6.3%, respectively, in our study group of established RA patients in daily clinical practice. Both the presence of sicca symptoms and sSS was associated with higher disease activity, impaired health-related quality of life and fatigue in RA patients. <h3>References</h3> Vitali et al. Ann Rheum Dis. 2002;61(6):554–8. <h3>Disclosure of Interest</h3> None declared
Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Deficiency
Authors: Jennifer Cuellar-Rodriguez, Dennis D. Hickstein, Jennifer K. Grossman, Mark Parta, Juan Gea-Banacloche, Christa S. Zerbe, Alexandra F Freeman, Steven M. Holland, Katherine R. Calvo
Journal: Blood (2014)
An Attempt to Enhance the Efficacy of Fludarabine, Mitoxantrone, Rituxan (FMR) with GM-CSF Priming: A Phase II Study.
Authors: Stacey E. Ban, Parameswaran Venugopal, Jamile M. Shammo, Sari Enschede, Solomon Adler, Teresa O’Brien, Stephanie A. Gregory
Journal: Blood (2004)
VNCOP-B (Etoposide, Mitoxantrone, Cyclophosphamide, Vincristine, Prednisolone, Bleomycin) Plus Rituximab Therapy in Elderly Patients with Aggressive B-Cell Non-Hodgkin Lymphoma: A Phase II Study of Efficacy and Safety
Authors: Kazuyoshi Ishii, Masahiro Manabe, Toshiya Yagi, Hirofumi Teshima, Yasuaki Nagare, Hidetsugu Kimura, Fumiaki Urase, Kunio Hayashi, Masaru Shibano, Machiko Tsukaguchi, Tatsuya Katsurada, Atsuko Mugitani, Hitoshi Kitayama, Shosaku Nomura
Journal: Blood (2008)
Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia
Authors: Monika Dolinska, Johannis Klang, Pingnan Xiao, Andranik Durgaryan, Lakshmi Sandhow, Anne-Sofie Johansson, Makoto Kondo, Stefan Deneberg, Johanna Ungerstedt, Katarina Le Blanc, Leif Stenke, Marja Ekblom, Ulla Stromberg, Satu Mustjoki, Soren Lehmann, Hong Qian
Journal: Blood (2015)
Abstract 12550: Persistent Relative Hypochromia is Associated With Adverse Outcomes in Non-anemic Patients With Heart Failure
Authors: Muhammad Hammadah, Yuping Wu, Lin Li, Stanley Hazen, W.H.Wilson Tang
Journal: Circulation (2015)

Background: We previously reported that functional iron deficiency, assessed by low mean corpuscular hemoglobin concentration (MCHC), has been associated with adverse outcomes in non-anemic patients with HF. Yet, the effect of change in MCHC levels on outcomes has not been studied before. Methods: We prospectively enrolled 1,579 subjects with HF undergoing coronary angiography, with 5-year follow-up. Blood indices [hemoglobin (Hb), MCHC, MCV, RDW] were assessed on enrollment and after 6 months of follow up by reviewing medical records. Anemia was defined as Hb levels &lt;12 g/dL in males, and &lt;11 g/dL in females. Results: In our population (age 66 ± 10 years, male 65%, CAD 75%), most patients were non-anemic (n=1,161, 73.5%). In non-anemic patients, mean Hb and median (IQR) MCHC were 13.3±1.2 g/dL and 34.2 (33.43-34.9) g/dL, respectively. Non-anemic HF patients with lower MCHC had higher mortality risk [Q1 vs Q4 Hazard ratio (HR) (95%CI) of 2.5(1.9-3.2), p&lt;0.001]. Total of 552 (35%) had follow up Hb levels with a mean time between baseline and follow up levels of 169.3 ± 41.6 days. HF severity (EF, BNP), outcomes and blood indices were similar in patients with and without follow up levels, suggesting good representation of the total population. Changes in MCHC levels was studied in non-anemic patients on baseline and follow up (n=318). Most patient with low MCHC at baseline (&lt;Q1, n=79) continued to have low MCHC on follow up (n=61), while half of the patients with high baseline MCHC (≥Q1, n=239) developed low MCHC on follow up (n=120). In comparison to patient with persistently high MCHC, patients with persistently low MCHC had a significantly increased mortality risk [HR(95%CI) of 3.5(2.1-6.1), p&lt;0.001]. All models remained significant even after adjusting for traditional CAD risk factors, EF and baseline blood indices. Conclusion: Relative hypochromia is an independent predictor of increase mortality in patients with HF, even in the setting of normal hemoglobin levels.
Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies
Authors: Lisette M. Schütte, Nils de Rooij, Hendrika C.A.M. Hazendonk, Ron A.A. Mathôt, Reinier M. van Hest, Frank W.G. Leebeek, Marjon H. Cnossen, Marieke J.H.A. Kruip
Journal: Blood (2015)
A Diet Rich in Alpha-Linolenic Acid Diminishes Atherosclerosis in Apolipoprotein E-Deficient Mice and Reduces Arachidonic Acid in Red Cell Membranes.
Authors: Christian M.R. Matter, Christine Lohmann, Eva Richter, Florian Leiber, Thomas F. Lüscher, Juerg H. Beer
Journal: Blood (2008)
Ruxolitinib Does Not Affect Bone Marrow Stromal Cell (BMSC) Clonogenicity and Growth but Interferes with JAK Signaling Under Inflammatory Conditions - Implications for Fibrosis in Myeloproliferative Diseases?
Authors: Dimitra Zacharaki, Hongzhe Li, Roshanak Ghazanfari, Stefan Scheding
Journal: Blood (2015)
OP0297 Knockout of Endothelin Type B Receptor Signaling Attenuates Bleomycin-Induced Skin Sclerosis in Mice
Authors: K. Akashi, J. Saegusa, S. Sendo, K. Nishimura, K. Tsuda, I. Naka, T. Okano, S. Takahashi, M. Nishida, Y. Ueda, A. Morinobu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Endothelin-1 (ET-1) is important in the pathogenesis of systemic sclerosis (SSc). It has been reported that plasma concentration of ET-1 are higher in SSc patients, and that endothelin receptor expression are also increased in lungs and skins in the patients. ET-1 binds two receptors, endothelin type A (ET<sub>A</sub>) and endothelin type B (ET<sub>B</sub>). Dual ET<sub>A</sub>/ET<sub>B</sub> receptor antagonists and a selective ET<sub>A</sub> receptor antagonist are used clinically to treat SSc, and the effect of these antagonists on fibroblast activation has been described. However, the role of ET<sub>B</sub> receptor signaling in fibrogenesis is less clear. <h3>Objectives</h3> This study was conducted to evaluate the profibrotic function of ET<sub>B</sub> receptor signaling in a murine model of bleomycin (BLM)-induced scleroderma. <h3>Methods</h3> We used ET<sub>B</sub> receptor–knockout (ET<sub>B</sub>KO) mice, which are genetically rescued from lethal intestinal aganglionosis by an ET<sub>B</sub> receptor transgene driven by the human dopamine β-hydroxylase (DβH)-gene promoter, and wild-type mice with DβH-ETB (WT). BLM or phosphate-buffered saline (PBS) was administered subcutaneously by osmotic minipump, and skin fibrosis was assessed by dermal thickness, subcutaneous fat atrophy, and alpha-smooth muscle actin (αSMA)-expressing myofibroblast count in the dermis. Dermal fibroblasts isolated from ET<sub>B</sub>KO and WT mice were cultured <i>in vitro</i>, stimulated with BLM or ET-1, and the expression of profibrotic genes was compared by quantitative PCR. <h3>Results</h3> Dermal thickness, subcutaneous fat atrophy, and myofibroblast counts in the dermis were significantly reduced in ET<sub>B</sub>KO mice compared to WT mice, after BLM treatment. Compared with wild-type, dermal fibroblasts isolated from ET<sub>B</sub>KO mice showed lower gene expressions of <i>αSMA</i> and <i>collagen 1α1</i> in response to BLM or ET-1 stimulation <i>in vitro.</i> <h3>Conclusions</h3> ET-1–ET<sub>B</sub> receptor signaling is involved in skin sclerosis and in collagen synthesis by dermal fibroblasts. <h3>Disclosure of Interest</h3> None declared
The Ratio of Pre-Transplant Serum Ferritin to the Units of Blood Transfused and Not Serum Hepcidin Strongly Correlates with Outcome After Allogeneic Hematopoietic Cell Transplantation In Patients with AML and MDS.
Authors: Haifa Kathrin Al-Ali, Nadja Jaekel, Rainer Krahl, Elvira Edel, Claudia Wickenhauser, Mark Westerman, Sabine Leiblein, Uwe Gerd Liebert, Marianne Hehme, Dietger W Niederwieser
Journal: Blood (2010)